BioNTech SE Stock
Model's Crash-Guard Rule Active. BioNTech SE has declined more than 15% from its 60-day high while the signal score is very low (below 25). In this constellation, the calculation model suspends its cautious signal and flags a contrarian phase. The background is a backward-looking observation from backtests: comparable extreme constellations showed above-average recoveries in the past, that is neither a forecast nor a guarantee.
Findings
- The distance to the 52-week high is 26.2%.
- The 30-day volatility of 38.1% sits in the upper third of the 416 titles in the universe.
Signal groups
Describes past price action, not a recommendation. As of October 26, 2026 at 08:03 AM, computed from the closing prices of the last trading day.
Key figures
- 1 day
- -1.7%
- 4 weeks
- -10.6%
- 52 weeks
- -17.6%
- Volatility 30 days
- 38.1%
- Max. decline 52 weeks
- -29.7%
- Distance to 52-week high
- -26.2%
- Sharpe ratio 1 year
- -0.46
In comparison
- The volatility sits in the upper third of the 44 titles in the Healthcare sector.
- The volatility sits in the upper third of the 133 titles on US exchanges.
The 16 signals
Each signal is one indicator. Tap it to see what it measures and what it currently shows for BioNTech SE.
EMA CrossoverCautious
For BioNTech SE, the fast moving average has crossed below the slow one. By this indicator's definition that corresponds to a downtrend, a description of past price action.
Compares a fast moving average to a slow one. When the fast is above the slow, the trend is positive. Period settings are automatically calibrated per asset class.
Read in the glossaryMA Trend Filter (200-day)Cautious
Checks whether the price is above or below its 200-day moving average, a look at the long-term trend.
ADX DirectionMixed
Shows whether upward or downward moves dominate in the trend whose strength the ADX measures (+DI versus -DI).
Read in the glossaryADX Trend Strength14.7Cautious
ADX stands at 14.7, a weak-trend environment, where directional signals carry less weight.
ADX does not measure direction, only how pronounced a trend is, regardless of whether it points up or down. We use it as a filter: only above a certain value does a trend count as strong enough to give other signals more weight. Direction itself comes from the separate ADX Direction signal.
Read in the glossaryRegression Intercept0.98Cautious
Fits a straight line through the closing prices of a fixed window and compares its level today with its level a few days earlier. A rising line describes an uptrend.
RSI (14)38.2Cautious
RSI stands at 38.2, in the zone this indicator defines as oversold, downward moves clearly outweighed upward moves over the last 14 trading days. In the past, counter-moves occurred more often in such zones than in neutral phases; that describes history, not the individual case.
The Relative Strength Index measures the ratio of upward to downward price movements over the last 14 trading days (Wilder smoothing) on a scale of 0 to 100. Our neutral zone is 45 to 55, tighter than the classic 30/70 band, outside of it the methodology reads the RSI as overbought or oversold.
Read in the glossaryMACD-0.2%Mixed
MACD stands at -0.2%, within the neutral zone around the threshold, no clear momentum in either direction.
MACD measures the gap between two exponentially smoothed averages. Our periods are 12/20/9 instead of the common 12/26/9, and the signal threshold is normalized to 0.3% of the current price rather than the raw MACD value, which keeps the threshold comparable across different price levels.
Read in the glossaryRate of Change-1.4%Cautious
BioNTech SE is -1.4% lower than 63 trading days ago, a negative medium-term price change.
Rate of Change measures the percentage price change over the last 63 trading days, roughly one quarter, a medium-term window, not a short-term daily or weekly read.
Read in the glossary52-Week High73.8%Mixed
BioNTech SE trades at 73.8% of its 52-week high, neither near the high nor far from it.
Measures how close the current price is to its highest point over the last 252 trading days, roughly one year. A value near 100% means the price is at or near its yearly high.
Read in the glossaryMomentum Oscillator-10.0%Cautious
BioNTech SE shows an accelerating downward move at -10.0%, recent price losses are larger than before.
Checks whether the recent price movement is accelerating or decelerating. Unlike Rate of Change, this indicator measures the pace of the change, not the change itself.
Read in the glossaryWilliams %R-94.0Mixed
Williams %R stands at -94.0, the price sits near the lower end of the 14-day trading range. This is the same zone classification a low RSI indicates.
Williams %R shows where the current price sits within the high-low range of the last 14 trading days. We read it as contrarian: a favorable signal only fires on a confirmed turn upward out of the oversold zone, not on any low value by itself, an extreme oversold reading alone never produces a cautious signal for us.
Read in the glossaryStochastic %K6.0Mixed
Stochastic %K stands at 6.0, currently without a confirmed crossover in either direction.
The Stochastic oscillator shows where the closing price sits within the recent trading range. A low or high value alone isn't enough for us: a signal only fires once %K and %D are both below 20 (or above 80) and %K is crossing upward (or downward), a confirmed turning point rather than a raw level.
Read in the glossaryVIX Level19.4Mixed
The VIX derives the expected fluctuation of the next 30 days from options on the S&P 500. It describes the market environment and is the same for every title.
Read in the glossaryVIX Rate of Change-2.7%Mixed
Measures how much the VIX has changed over the last trading days. A fast rise stands for quickly growing expected fluctuation. The same for every title.
Read in the glossaryHY SpreadCautious
The yield premium of high-yield bonds over government bonds, a gauge of how the credit market prices default risk. It describes the market environment and is the same for every title.
Read in the glossaryRelative Strength0.95Cautious
BioNTech SE stands at 0.95, below the reference index, price performance over the period was weaker than the reference index's.
Compares price performance over a medium-term period against a broad stock market index as a reference. A value above 1.0 means stronger performance than the reference index, below 1.0 means weaker.
Analyze BioNTech SE in your own portfolio
edgio computes what you see here for BioNTech SE for every position in your portfolio, and gets in touch when something turns.
- Watch BioNTech SE: score and 16 signals on your watchlist, up to 5 titles
- Your own portfolio with up to 3 positions: score, risk and spread
- Weekly overview by email
- An email as soon as the score of BioNTech SE turns
- Signal history of BioNTech SE in hindsight
- Backtest: how the levels would have come through past crises with BioNTech SE
- Risk budget with a loss limit, up to 50 positions
7 days of Pro free, then Free automatically. No credit card.
How the score comes about
- 0116 signals per title
Trend, momentum, oscillators and the market environment (VIX, credit market), computed every trading day after the close from the closing prices.
- 02One score from 0 to 100
A weighted average, not a majority vote. From 70 Positive, 40 to 69 Mixed, below 40 Cautious.
- 03Tested in hindsight
The same methodology was tested in 12 time windows from 2014 to 2025, on 64 portfolios.
We do not publish the weighting of the individual signals. Methodology in detail
About BioNTech SE
BioNTech is a German next-generation biotechnology company developing individualized immunotherapies for cancer and serious infectious diseases. The company achieved global prominence by co-developing the first approved mRNA COVID-19 vaccine, Comirnaty, in partnership with Pfizer. Current commercial revenue is generated primarily from profit shares and royalties received from commercial partner Pfizer for vaccine sales. The company's strategic focus is advancing its clinical oncology pipeline, which includes individualized mRNA cancer vaccines, antibody-drug conjugates, and cell therapies for solid tumors. The company is based in Mainz, Germany.
Technical reading
Technical analysis for BioNTech SE stock (BNTX), trend direction, momentum strength and risk metrics based on 16 quantitative signals, updated daily.
Trend. 0 of 5 trend signals read positive. ADX at 14.7 indicates a weak trend environment. The price is below the 200-day moving average.
Momentum. 0 of 5 momentum signals read positive. RSI at 38.2 is in the oversold zone.
Risk Metrics. 30-day volatility at 38.1%. price 26% below its 52-week high. Sharpe Ratio at -0.46 indicates a negative risk-adjusted return over 12 months.
Market Environment. VIX at 19.4 indicates normal expected market volatility. The high-yield spread signal reads cautious.
Sector Context. 52-week return of -17.6% is below the Healthcare sector average of 25.9%. Ranked #44 of 44 Healthcare titles by signal score.
Questions about BioNTech SE
How does BioNTech SE stand according to the edgio signals?
The signal score of BioNTech SE is 19 out of 100, which is the state Cautious. 0 of 16 signals are positive. As of October 26, 2026 at 08:03 AM.
What is the RSI of BioNTech SE?
The RSI (14) of BioNTech SE is 38.2. Downward moves outweighed upward moves over the last 14 trading days. At edgio the neutral zone is 45 to 55.
Is this a forecast or a recommendation?
No. The signals describe past price action and the market environment. They do not predict the future and do not consider your personal situation. You make your own decisions.
How often is the score computed?
Every trading day after the close. The page shows the state of the latest computation.
In the Healthcare sector
Each cell is one title, sorted by signal score. BioNTech SE is highlighted.
Compare with another title
Two titles side by side, with the values of this page.
More Healthcare titles
Notes
The information presented does not constitute investment advice and should not be construed as a solicitation to buy or sell financial instruments. Past performance is not a reliable indicator of future results. Any investment decision should be based on your own research and, where appropriate, professional advice. Marvin Waraschitz, founder of edgio, currently holds no position in BNTX.
The values are computed algorithmically from public market data (closing prices, VIX, credit spreads). Logos by Elbstream. Methodology & full disclaimer
Methodology & Background
- RSI Aktien: Was der Relative-Strength-Index misst, was er nicht misst und warum die Standardschwellen oft falsch eingesetzt werden (Deutsch) →
- EMA Crossover erklärt: Wie das Signal funktioniert und welche Perioden Tests bestanden haben (Deutsch) →
- 16 Signale, 148 Aktien, 12 Jahre: Was unsere Backtests wirklich zeigen (Deutsch) →